Ashvattha Therapeutics is a clinical-stage biotechnology company specializing in precision nanomedicine to treat inflammatory diseases, ophthalmology conditions, and neurological disorders. Their innovative approach uses hydroxyl dendrimers, a type of nanostructure, to specifically target diseased cells while sparing healthy ones. This technology enables precise drug delivery, crossing biological barriers like the blood-retinal and blood-brain barriers, minimizing off-target effects and invasive treatments.